Cambridge Investment Research Advisors
ADIL

Cambridge Investment Research Advisors’s Adial Pharmaceuticals ADIL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,080
Closed -$27K – 3499
2024
Q4 		$27K Buy
+1,080
New +$28.1K ﹤0.01% 3405

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
1IA
1620 Investment Advisors Plymouth, Massachusetts $161M AUM 30.15% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cambridge Investment Research Advisors's ADIL Position: Q1 2025 in Review

Cambridge Investment Research Advisors sold out of Adial Pharmaceuticals (ADIL) in Q1 2025, closing a stake of 1,080 shares — an estimated $27K sold.

Cambridge Investment Research Advisors first reported a position in ADIL in Q4 2024 and held it in 1 quarter. The position peaked at $27K in Q4 2024. 12 funds tracked by Wall St. Rank hold ADIL as of Q1 2025.

  • Cambridge Investment Research Advisors reported no remaining Adial Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,080 Adial Pharmaceuticals shares in Q1 2025, an estimated $27K.
  • Cambridge Investment Research Advisors first reported a position in Adial Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Adial Pharmaceuticals position peaked at $27K in Q4 2024.
  • 12 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2025, filed 22 Apr 2025.